IQVIA HOLDINGS INC.
Last · NYSE$262.16+1.48 (+0.57%)close · yahoo · 13h ago
Market cap$43.15B164.6M sh
P/E · TTM32.6fwd 18.2 · eps 8.05
Beta1.17vs S&P 500
Div yield0.00%annual · TTM
52w range
$154.50$277.40
Volume846.2Ksession
| Revenue | $17.0B |
|---|---|
| Operating income | $2.2B |
| Net income | $1.4B |
| Free cash flow | $2.2B |
| Operating margin | 13.0% |
| Net margin | 8.1% |
| Return on equity | 22.3% |
| Period | TTM 2026-06-30 |
Loading chart…
OpenFilings analyst
Our analyst
From latest 10-K · 2026-02-17
- Backlog Strength
- Healthcare Data Moat
- Research Development Slowdown
- High Leverage
- Margin Pressure
- Acquisition Spending
- Data Supplier Dependence
Red flags
- Debt was $15.8 billion at year-end versus $1.98 billion of cash; $1.84 billion of debt matures in 2026 and $1.794 billion in 2027.
- IQVIA had $800 million drawn under its $2.0 billion revolving facility, while approximately 30% of revenue is denominated in non-U.S. currencies, creating both refinancing and foreign-exchange sensitivity.
- Research and development contracts can generally be terminated with 30 to 90 days’ notice, exposing revenue, utilization and profitability to cancellations or delays.
- The company relies on third-party data suppliers; although no single supplier is material, disruption or restrictions across suppliers representing a significant amount of data could impair services and results.
Upcoming earnings
1:30 PM UTC+1
Period
Sep 2026
Est. EPS
$3.27
Est. revenue
4.4B
Earnings transcripts
Documents
FormReporting forFiledFlags